Sacral Neuromodulation in Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy of neuromodulation for treatment of chronic constipation and fecal incontinence in pediatric patients and to evaluate the differences between the invasive vs. non-invasive approach.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation

NCT04710433

Chronic Constipation With Overflow Encopresis With Constipation and Overflow Incontinence Hirschprung's Disease +1 more

COMPLETED NA

Posterior Tibial Nerve Stimulation for Children With Pelvic Floor Dyssynergia

NCT06528470

Constipation Fecal Incontinence in Children Pelvic Floor Dyssynergia

RECRUITING NA

Sacral Nerve Stimulation for Anal Incontinence and Bowel Control

NCT00200005

Fecal Incontinence and Constipation

COMPLETED PHASE4

Effect of Pudendal Nerve Electrical Stimulation on Fecal Incontinence in Children With Repaired Anorectal Malformation

NCT07099339

Fecal Incontinence (FI) Anorectal Malformations

COMPLETED NA

Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective

NCT03261622

Faecal Incontinence Fecal Incontinence

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are selected according to the eligibility requirements. After obtaining informed consent off-label use and potential risks of sacral neuromodulation, all included patients and next of kin give written informed consent to the study.

At baseline, patients are randomized to one of the two predefined subgroups: either invasive sacral neuromodulation or non-invasive sacral neuromodulation. Clinical symptoms and outcome variables are compared regarding the beginning of non-invasive sacral neuromodulation or the implantation of the tined lead electrode. Patients are closely monitored within 6 months. Treatment success is evaluated in routine clinical check-ups (week 4/8/12 and 24) and via specialized questionnaires and bowel movement diaries. Quality of life is evaluated at baseline and after 12 and 24 weeks of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Constipation With Overflow Encopresis With Constipation and Overflow Incontinence Hirschsprung's Disease Anorectal Malformations Sacral Dysgenesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sacral Neuromodulation

Sacral neuromodulation is surgically implanted within two surgeries:

1. Implantation of the final electrode (tined-lead electrode): This electrode is implanted to neuronal fibers of S3/4. Both sides are tested intraoperatively, the side with a sufficient response at lower intensity levels is finally implanted. Stimulation is conducted via an external pulse generator.
2. Implantation of the internal pacemaker system 4 weeks after the electrode's implantation.

Stimulation parameters: Single current, frequency 15Hz, duration 210μs. Stimulation intensity is individually determined beyond the pain threshold (adjustable amplitude between 0-10mA, depending on the intraoperative response).

Start point of clinical evaluation is time of implantation of tined lead electrode.

Medical and behavioral therapy is to be continued as started before intervention.

Group Type ACTIVE_COMPARATOR

Invasive Sacral Neuromodulation

Intervention Type DEVICE

Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)

Non-invasive Sacral Neuromodulation

Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field by single current with a 15 Hz frequency for a duration of 210μs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).

Start point of clinical evaluation is start of external stimulation.

Medical and behavioral therapy is to be continued as started before intervention.

Group Type ACTIVE_COMPARATOR

Non-invasive Sacral Neuromodulation

Intervention Type DEVICE

External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Invasive Sacral Neuromodulation

Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)

Intervention Type DEVICE

Non-invasive Sacral Neuromodulation

External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 2-17 years
* informed consent
* chronic constipation according to the ROME IV criteria for more than 3 months with or without encopresis/soiling despite underlying diseases such as slow-transit constipation, rectal evacuation disorders or Hirschsprung's disease.
* refractory to conventional treatment in an appropriate weight-adapted application (training for bowel movements, lifestyle changes, pelvic floor training, pharmacological options)
* in cases of Hirschsprung's disease: diagnosis confirmed histologically by rectal biopsies and in case of resection of an aganglionic segement: period between surgery and SNM at least 1 year
* in cases of anorectal malformation or mechanical obstruction: post-surgical status: period between surgery and SNM at least 1 year

Exclusion Criteria

* metabolic, inflammatory, and hormonal causes for chronic constipation
* toxic megacolon or further emergencies, which must be treated surgically
* sacral fractures or substantial differences in the sacral anatomy
* inflammatory bowel disorders
* rectal prolapse
* neuronal malignancies under medical and radiation therapy
* seizures

Minimum Eligible Age

2 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No